SHTG Daily Digest — Weiss Lab

A thin cycle on both fronts — no new top-tier lipid papers after dedup, so this episode leans on two next-tier LPL papers (one showing FCS patients from Ionis' Balance trial carry less Lp(a) than genetics would predict), and the trade press had no new SHTG, Arrowhead, Alnylam or Ionis stories in the last five days.

A thin cycle on both fronts — the only top-tier lipid paper is the NEJM letter showing one-year durability of CTX310, CRISPR Therapeutics' one-time ANGPTL3 knockout, and the trade press ran no new SHTG, Arrowhead, Alnylam or Ionis stories in the five-day window.

A thin cycle on both sides: no top-tier lipid papers, but the next tier brought a network meta-analysis finding that faster triglyceride lowering in HTG pancreatitis has not been shown to improve hard outcomes, a large CT-plus-triglyceride model for predicting severe HTG pancreatitis, and a case series on plasma infusion for infantile ApoC-II deficiency; on the industry side there was no new SHTG, Arrowhead, Alnylam or Ionis lipid news, and the only fresh item was ADARx's $446M IPO, the first US IPO from an RNAi company in more than a decade.

Another thin cycle: no top-tier lipid papers, but the next tier brought a high-specificity Cas12a editing study that knocked out Angptl3 in mice and a 526-patient study showing that how fast triglycerides fall after admission predicts severity in hypertriglyceridemic pancreatitis; on the industry side there was no new SHTG news, and the only fresh item was a second Ionis-partnered Phase 3 win of the week, Otsuka's ulefnersen in FUS-ALS.

A thin cycle on both fronts — the lipid literature offered only next-tier work (an ANGPTL3 base-editing delivery study, an APOC3 variant association in Indian MASLD, and two clinical-care papers on hypertriglyceridemia), and the industry side produced no new SHTG news, with the only fresh item being Ionis's partnered antisense drug sefaxersen hitting its Phase 3 interim endpoint in IgA nephropathy with Roche.

It's a thin cycle on both fronts — the only notable lipid-biology paper this week is a new CRISPR rabbit model of APOA5-driven hypertriglyceridemia, and the SHTG-relevant industry press was quiet, with searches turning up only stories already covered in recent episodes.

A quiet cycle on both fronts — the lipid literature offered only next-tier evidence (CRISPR/base-editing for ANGPTL3, plasma exchange for SHTG crises, and an erythritol-apoC-III diet link), and the industry side had no new Arrowhead/Alnylam/Ionis news beyond last cycle's already-covered Novartis/Ionis pelacarsen failure.

A new JACC: Basic to Translational Science analysis shows ApoC-III inhibition with olezarsen strips triglycerides and cholesterol out of Lp(a) particles without lowering Lp(a) mass itself, while two case reports underline how hard SHTG still is to diagnose and treat at the bedside — and it was a quiet week for Arrowhead, Alnylam, and Ionis in the trade press.

A quiet cycle on both fronts — PubMed's top-tier journals produced zero SHTG/ANGPTL/APOC3/LPL hits this week (next-best-tier picks below cover ANGPTL3 inhibition, lipodystrophy genetics, and LPL biochemistry), and none of the tracked trade outlets published fresh news on SHTG, Arrowhead, Alnylam, or Ionis in the last five days.

No top-tier journal papers cleared the bar this cycle, but next-tier literature offered genetics-to-therapy signal on FCS (a novel APOA5 variant and an ApoC-II case series) alongside two olezarsen/zodasiran commentary pieces, while the industry side was quiet — everything found in the 5-day window on Arrowhead, Alnylam, or Ionis's lipid programs had already been covered in the prior cycle.